Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 24,700 shares, a drop of 56.7% from the February 28th total of 57,000 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 198,900 shares, the days-to-cover ratio is presently 0.1 days.

Astellas Pharma Stock Up 0.3 %

Shares of OTCMKTS:ALPMY opened at $9.93 on Friday. The firm has a market cap of $17.97 billion, a PE ratio of -45.13 and a beta of 0.29. The company has a fifty day simple moving average of $9.73 and a 200 day simple moving average of $10.45. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. Astellas Pharma has a 12-month low of $9.05 and a 12-month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. On average, equities research analysts anticipate that Astellas Pharma will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.